RxDoctor Payments Data

Sudarshan Velpari

Internal Medicine · Jersey City, NJNPI 1235450263

Payments from drug & device makers

$18,674in general payments, 2019–2025

Across 1,339 payments — averaging $13.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • AbbVie$2K
  • Novo Nordisk$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Amgen$921
  • Merck$810
  • plus $9K from 41 others

What the payments were for

  • Food & beverage$18,662100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,674 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$172,890
Medicare patients
295
Services billed
1,427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin68$87,220
OzempicSemaglutide51$64,228
MounjaroTirzepatide43$49,707
FarxigaDapagliflozin Propanediol22$31,165
JanuviaSitagliptin Phosphate34$30,518
EliquisApixaban19$26,031
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$25,211
JanumetSitagliptin Phos/Metformin Hcl17$18,103
TrintellixVortioxetine Hydrobromide18$17,544
Breo ElliptaFluticasone/Vilanterol29$14,441
VascepaIcosapent Ethyl20$14,202
SymbicortBudesonide/Formoterol Fumarate13$6,271
Rosuvastatin Calcium240$3,237
Icosapent Ethyl12$3,176
Atorvastatin Calcium229$2,523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$764$87,22068 claims
Novo NordiskOzempic$1,905$64,22851 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$2,829$62,64767 claims
Lilly USA, LLCMounjaro$781$49,70743 claims
MerckJanuvia, Janumet$810$48,62251 claims
PfizerEliquis$174$26,03119 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$319$17,54418 claims
GSKBreo Ellipta$463$14,44129 claims
AbbVieSynthroid$2,183$1,50723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Jersey City

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →